Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Gasol-Cudós, Ariadna
8  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

Selection of neoadjuvant treatment based on the 21-GENE tes..:

Serafin Morales Murillo ; Ariadna Gasol Cudos ; Joel Veas Rodriguez...
http://www.sciencedirect.com/science/article/pii/S0960977621000023.  , 2021
Link: https://doi.org/10.1016/..
 
?
2

Survival analysis of bevacizumab plus taxane treatment in l..:

Serafin Morales Murillo ; Ariadna Gasol Cudos ; Joel Veas Rodriguez...
https://www.future-science.com/doi/10.2144/fsoa-2020-0146.  , 2021
Link: https://doi.org/10.2144/..
 
?
3

Immuno-priming durvalumab with bevacizumab in HER2-negative..:

Miguel Quintela-Fandino ; Esther Holgado ; Luis Manso...
http://link.springer.com/article/10.1186/s13058-020-01362-y.  , 2020
Link: https://doi.org/10.1186/..
 
?
4

Immuno-priming durvalumab with bevacizumab in HER2-negative..:

Quintela-Fandino, Miguel ; Holgado, Esther ; Manso, Luis...
Breast Cancer Research.  , 2021
Link: http://hdl.handle.net/10..
 
?
5

Selection of neoadjuvant treatment based on the 21-GENE tes..:

Morales Murillo, Serafin ; Gasol Cudos, Ariadna ; Veas Rodriguez, Joel...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900764/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
6

Immuno-priming durvalumab with bevacizumab in HER2-negative..:

Quintela-Fandino, Miguel ; Holgado, Esther ; Manso, Luis...
Ministerio de Economía, Industria y Competitividad PI16/00354.  , 2020
Link: https://ddd.uab.cat/reco..
 
?
7

Immuno-priming durvalumab with bevacizumab in HER2-negative..:

Holgado, Esther ; Manso, Luis ; Morales, Serafin...
Publisher's version.  , 2020
Link: https://hdl.handle.net/2..
 
?
8

ICO-ICS Praxi per al tractament mèdic i amb irradiació de l..:

Arribas Garcia, Lorena ; Berenguer Frances, Miguel Angel ; Calvo-Campos, Mariona...
ICO-ICSPraxi;.  , 2018
Link: https://hdl.handle.net/1..
 
1-8